Your browser doesn't support javascript.
loading
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.
Li, Jing; Du, Heyue; Wang, Yang; Aertgeerts, Bert; Guyatt, Gordon; Hao, Qiukui; Shen, Yanjiao; Li, Ling; Su, Na; Delvaux, Nicolas; Bekkering, Geertruida; Khan, Safi U; Riaz, Irbaz B; Vandvik, Per Olav; Su, Baihai; Tian, Haoming; Li, Sheyu.
Afiliación
  • Li J; Department of Endocrinology and Metabolism, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Du H; Department of Endocrinology and Metabolism, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Wang Y; Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Aertgeerts B; Department of Endocrinology and Metabolism, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Guyatt G; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Hao Q; Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, and School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.
  • Shen Y; Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, and School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada.
  • Li L; Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Su N; Department of Endocrinology and Metabolism, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Delvaux N; Department of Endocrinology and Metabolism, Chinese Evidence-Based Medicine Center, Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Bekkering G; Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Khan SU; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Riaz IB; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Vandvik PO; Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Pennsylvania, USA.
  • Su B; Mayo Clinic Arizona and Brigham and Women hospital, Harvard Medical School, Boston, New York, USA.
  • Tian H; Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.
  • Li S; Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Heart ; 108(16): 1296-1302, 2022 07 27.
Article en En | MEDLINE | ID: mdl-35508401
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de PCSK9 Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de PCSK9 Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article